Biomarkers in rheumatic diseases: How can they facilitate diagnosis and assessment of disease activity?

Chandra Mohan, Shervin Assassi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Serological and proteomic biomarkers can help clinicians diagnose rheumatic diseases earlier and assess disease activity more accurately. These markers have been incorporated into the recently revised classification criteria of several diseases to enable early diagnosis and timely initiation of treatment. Furthermore, they also facilitate more accurate subclassification and more focused monitoring for the detection of certain disease manifestations, such as lung and renal involvement. These biomarkers can also make the assessment of disease activity and treatment response more reliable. Simultaneously, several new serological and proteomic biomarkers have become available in the routine clinical setting-for example, a protein biomarker panel for rheumatoid arthritis and a myositis antibody panel for dermatomyositis and polymyositis. This review will focus on commercially available antibody and proteomic biomarkers in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (scleroderma), dermatomyositis and polymyositis, and axial spondyloarthritis (including ankylosing spondylitis). It will discuss how these markers can facilitate early diagnosis as well as more accurate subclassification and assessment of disease activity in the clinical setting. The ultimate goal of current and future biomarkers in rheumatic diseases is to enable early detection of these diseases and their clinical manifestations, and to provide effective monitoring and treatment regimens that are tailored to each patient's needs and prognosis.

Original languageEnglish (US)
Article numberh5079
JournalBritish Medical Journal
Volume351
DOIs
StatePublished - Nov 26 2015

Fingerprint

Rheumatic Diseases
Biomarkers
Proteomics
Early Diagnosis
Dermatomyositis
Systemic Scleroderma
Rheumatoid Arthritis
Myositis
Antibodies
Ankylosing Spondylitis
Systemic Lupus Erythematosus
Therapeutics
Kidney
Lung
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biomarkers in rheumatic diseases : How can they facilitate diagnosis and assessment of disease activity? / Mohan, Chandra; Assassi, Shervin.

In: British Medical Journal, Vol. 351, h5079, 26.11.2015.

Research output: Contribution to journalArticle

@article{9c1a149bddb6417a99527b3d39612b84,
title = "Biomarkers in rheumatic diseases: How can they facilitate diagnosis and assessment of disease activity?",
abstract = "Serological and proteomic biomarkers can help clinicians diagnose rheumatic diseases earlier and assess disease activity more accurately. These markers have been incorporated into the recently revised classification criteria of several diseases to enable early diagnosis and timely initiation of treatment. Furthermore, they also facilitate more accurate subclassification and more focused monitoring for the detection of certain disease manifestations, such as lung and renal involvement. These biomarkers can also make the assessment of disease activity and treatment response more reliable. Simultaneously, several new serological and proteomic biomarkers have become available in the routine clinical setting-for example, a protein biomarker panel for rheumatoid arthritis and a myositis antibody panel for dermatomyositis and polymyositis. This review will focus on commercially available antibody and proteomic biomarkers in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (scleroderma), dermatomyositis and polymyositis, and axial spondyloarthritis (including ankylosing spondylitis). It will discuss how these markers can facilitate early diagnosis as well as more accurate subclassification and assessment of disease activity in the clinical setting. The ultimate goal of current and future biomarkers in rheumatic diseases is to enable early detection of these diseases and their clinical manifestations, and to provide effective monitoring and treatment regimens that are tailored to each patient's needs and prognosis.",
author = "Chandra Mohan and Shervin Assassi",
year = "2015",
month = "11",
day = "26",
doi = "10.1136/bmj.h5079",
language = "English (US)",
volume = "351",
journal = "The BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Biomarkers in rheumatic diseases

T2 - How can they facilitate diagnosis and assessment of disease activity?

AU - Mohan, Chandra

AU - Assassi, Shervin

PY - 2015/11/26

Y1 - 2015/11/26

N2 - Serological and proteomic biomarkers can help clinicians diagnose rheumatic diseases earlier and assess disease activity more accurately. These markers have been incorporated into the recently revised classification criteria of several diseases to enable early diagnosis and timely initiation of treatment. Furthermore, they also facilitate more accurate subclassification and more focused monitoring for the detection of certain disease manifestations, such as lung and renal involvement. These biomarkers can also make the assessment of disease activity and treatment response more reliable. Simultaneously, several new serological and proteomic biomarkers have become available in the routine clinical setting-for example, a protein biomarker panel for rheumatoid arthritis and a myositis antibody panel for dermatomyositis and polymyositis. This review will focus on commercially available antibody and proteomic biomarkers in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (scleroderma), dermatomyositis and polymyositis, and axial spondyloarthritis (including ankylosing spondylitis). It will discuss how these markers can facilitate early diagnosis as well as more accurate subclassification and assessment of disease activity in the clinical setting. The ultimate goal of current and future biomarkers in rheumatic diseases is to enable early detection of these diseases and their clinical manifestations, and to provide effective monitoring and treatment regimens that are tailored to each patient's needs and prognosis.

AB - Serological and proteomic biomarkers can help clinicians diagnose rheumatic diseases earlier and assess disease activity more accurately. These markers have been incorporated into the recently revised classification criteria of several diseases to enable early diagnosis and timely initiation of treatment. Furthermore, they also facilitate more accurate subclassification and more focused monitoring for the detection of certain disease manifestations, such as lung and renal involvement. These biomarkers can also make the assessment of disease activity and treatment response more reliable. Simultaneously, several new serological and proteomic biomarkers have become available in the routine clinical setting-for example, a protein biomarker panel for rheumatoid arthritis and a myositis antibody panel for dermatomyositis and polymyositis. This review will focus on commercially available antibody and proteomic biomarkers in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (scleroderma), dermatomyositis and polymyositis, and axial spondyloarthritis (including ankylosing spondylitis). It will discuss how these markers can facilitate early diagnosis as well as more accurate subclassification and assessment of disease activity in the clinical setting. The ultimate goal of current and future biomarkers in rheumatic diseases is to enable early detection of these diseases and their clinical manifestations, and to provide effective monitoring and treatment regimens that are tailored to each patient's needs and prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84952685286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952685286&partnerID=8YFLogxK

U2 - 10.1136/bmj.h5079

DO - 10.1136/bmj.h5079

M3 - Article

C2 - 26612523

AN - SCOPUS:84952685286

VL - 351

JO - The BMJ

JF - The BMJ

SN - 0959-8146

M1 - h5079

ER -